EL-26· Research peptide
Ipamorelin
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
EL-26· Research peptide
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
No reviews yet. Be the first to share your experience.
Research Use Only (RUO)
Tier I · Synthesis QC
Tier I · Synthesis QC
In-house · per step
RP-HPLC, MS confirmation, sequence verification in cleanroom.
Tier II · In-process
Tier II · In-process
Batch · final
Identity, purity, and assay before release.
Tier III · Third-party lab
Tier III · Third-party lab
External · independent
HPLC, ICP-MS, and microbiology by accredited lab.
953
satisfied
99.41%
Avg. purity 2026
4.8 ★
Store rating
EL-26 · Reference data
Selektiver GHS-R1a-Agonist (Pentapeptid)
Aliases: NN703
Ipamorelin is a synthetic pentapeptide made up of five amino acids and belongs to the growth hormone secretagogues. In the late 1990s it was described as the first selective GH secretagogue: in the experiments at the time, it stimulated the release of growth hormone (GH) without stimulating the other pituitary hormones to the same extent. This very question of selectivity is what keeps the molecule interesting today.
Its site of action is the GHRP and ghrelin receptor pathway. Ipamorelin belongs to the ghrelin mimetics and binds to the corresponding receptor on the somatotropic cells of the pituitary. There it sets a cellular signaling cascade in motion that ends in the secretion of GH. Because this pathway runs through a different receptor from the one GHRH uses, its profile differs from that of a GHRH analog.
GH release is part of a coordinated regulatory loop: GHRH drives it, somatostatin restrains it, and the ghrelin pathway provides its own input. A secretagogue that primarily uses this third pathway makes the somatotropic axis accessible in a targeted way.
In the original studies, Ipamorelin was tested on rat pituitary cells, in rats and in pigs. GH release was observed. The comparison with GHRP-2 and GHRP-6 was particularly informative: with Ipamorelin, the ACTH and cortisol response was lower than with the two reference peptides (original study by Raun and colleagues).
These findings come from cellular and animal models. They show how the peptide acts in these systems, and they are not evidence that cortisol or adverse effects remain unaffected in humans.
In 1999, Ipamorelin was investigated in an early clinical study in healthy male volunteers. An acute episode of GH release was measured; at the same time, the compound's time course in the body could be described with a pharmacokinetic-pharmacodynamic model (study by Gobburu and colleagues). For research, this is a robust indication that the human GH axis responds to the peptide.
However, an acute hormone surge remains a biomarker. The study was small and limited to healthy men, as is usual for early clinical trials. The hormone level says nothing about muscle mass, body fat, sleep quality or recovery; that would require studies with precisely these endpoints.
Ghrelin and GH secretagogues do not affect only the pituitary. The receptor pathway is also involved in controlling gastrointestinal motility, and delayed bowel activity after abdominal surgery is a clinically relevant problem. This connection raised the question of whether a ghrelin mimetic could favorably influence postoperative ileus after bowel resection.
In 2014, a multicenter, double-blind, placebo-controlled phase II study tested Ipamorelin in patients after bowel resection; 117 people were enrolled (phase II study by Beck and colleagues). Time to the first tolerated solid meal was numerically shorter with Ipamorelin, but the primary comparison did not reach statistical significance, with p = 0.15.
For this endpoint, the study therefore remains a negative finding: a trend without established efficacy. The intravenous study formulation and the surgical population are also important; the result cannot be transferred to ordinary digestive complaints.
Ipamorelin is available in variants with 5 mg and 10 mg per vial. Anyone who needs the peptide for their own research project can buy Ipamorelin and select the amount they need in the shop.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.41% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
Ipamorelin is a synthetic pentapeptide made up of five amino acids. It belongs to the growth hormone secretagogues and stimulates GH release through the GHRP and ghrelin receptor pathway.
In comparative studies in pigs, Ipamorelin stimulated GH release while the ACTH and cortisol response was lower than with the two reference peptides. This selectivity has been shown in animal models and cannot be readily transferred to humans.
In an early clinical study with healthy male volunteers, acute GH release was measured and the compound's time course in the body was modeled. Whether this leads to benefits for body composition, sleep or recovery remains unresolved.
Because the ghrelin receptor pathway also influences bowel motility. The phase II study in patients after bowel resection showed a numerically shorter time to the first tolerated meal, but no statistically significant difference from placebo.
Ipamorelin is available in variants with 5 mg and 10 mg per vial.